MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow An erratum has been published
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yu, C.
Right arrow Articles by Grant, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yu, C.
Right arrow Articles by Grant, S.

Vol. 60, Issue 1, 143-154, July 2001

Sequence-Dependent Potentiation of Paclitaxel-Mediated Apoptosis in Human Leukemia Cells by Inhibitors of the Mitogen-Activated Protein Kinase Kinase/Mitogen-Activated Protein Kinase Pathway

Chunrong Yu, Shujie Wang, Paul Dent, and Steven Grant

Departments of Medicine (C.Y., S.G.), Pharmacology (S.G.), Biochemistry (S.W., S.G.), and Radiation Oncology (P.D.), Medical College of Virginia, Virginia Commonwealth University, Richmond, Virginia

Effects of inhibitors of the mitogen-activated protein kinase kinase/mitogen-activated protein kinase (MEK/MAPK) cascade have been examined in relation to paclitaxel-induced apoptosis in human monocytic leukemia cells (U937). Cells treated with paclitaxel (250 nm; 6 h) followed by PD98059 (40 µM; 15 h) exhibited a significant increase in mitochondrial dysfunction (e.g., cytochrome c release), caspase activation, poly ADP-ribose polymerase cleavage, and apoptosis, whereas pretreatment of cells with PD98059 reduced lethality. Similar results were obtained with other MEK/MAPK inhibitors (e.g., U0126 and PD184352). Subsequent exposure of paclitaxel-treated cells to PD98059 did not enhance dephosphorylation/activation of p34cdc2 but diminished expression of the antiapoptotic protein Mcl-1. The caspase inhibitor ZVAD-fmk opposed potentiation of paclitaxel-induced loss of mitochondrial membrane potential (Delta psi m) and apoptosis by PD98059, but not cytochrome c release. Paclitaxel treatment induced sustained phosphorylation/activation of MAPK, an effect prevented by subsequent, but not prior, exposure to PD98059. Paclitaxel treatment also induced c-Jun N-terminal kinase phosphorylation, but this effect was enhanced only slightly by subsequent PD98059 administration. Although paclitaxel alone failed to induce p38 MAPK activation, subsequent (but not prior) exposure to PD98059 induced a dramatic increase in p38 MAPK phosphorylation. Moreover, coadministration of the p38 MAPK inhibitors SB203580 and SB202190 abrogated the increase in paclitaxel-mediated apoptosis induced by PD98059. Finally, subsequent PD98059 exposure increased, whereas prior exposure decreased inhibition of clonogenicity by paclitaxel. Together, these findings suggest that subsequent exposure of paclitaxel-treated U937 cells to MEK/MAPK inhibitors induces perturbations in signaling pathways, particularly the p42/44 MAPK and p38 MAPK cascades, that lower the threshold for mitochondrial injury and induction of cell death.

Copyright © 2001 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 BloodHome page
P. Lunghi, N. Giuliani, L. Mazzera, G. Lombardi, M. Ricca, A. Corradi, A. M. Cantoni, L. Salvatore, R. Riccioni, A. Costanzo, et al.
Targeting MEK/MAPK signal transduction module potentiates ATO-induced apoptosis in multiple myeloma cells through multiple signaling pathways
Blood, September 15, 2008; 112(6): 2450 - 2462.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
K. Katayama, S. Yoshioka, S. Tsukahara, J. Mitsuhashi, and Y. Sugimoto
Inhibition of the mitogen-activated protein kinase pathway results in the down-regulation of P-glycoprotein
Mol. Cancer Ther., July 1, 2007; 6(7): 2092 - 2102.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Z. N. Demidenko, D. Halicka, J. Kunicki, J. A. McCubrey, Z. Darzynkiewicz, and M. V. Blagosklonny
Selective Killing of Adriamycin-Resistant (G2 Checkpoint-Deficient and MRP1-Expressing) Cancer Cells by Docetaxel
Cancer Res., May 15, 2005; 65(10): 4401 - 4407.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. Hahn, W. Li, C. Yu, M. Rahmani, P. Dent, and S. Grant
Rapamycin and UCN-01 synergistically induce apoptosis in human leukemia cells through a process that is regulated by the Raf-1/MEK/ERK, Akt, and JNK signal transduction pathways
Mol. Cancer Ther., March 1, 2005; 4(3): 457 - 470.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
G. Li, Y. Xiao, and L. Zhang
Cocaine Induces Apoptosis in Fetal Rat Myocardial Cells through the p38 Mitogen-Activated Protein Kinase and Mitochondrial/Cytochrome c Pathways
J. Pharmacol. Exp. Ther., January 1, 2005; 312(1): 112 - 119.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. R. Jazirehi, M. I. Vega, D. Chatterjee, L. Goodglick, and B. Bonavida
Inhibition of the Raf-MEK1/2-ERK1/2 Signaling Pathway, Bcl-xL Down-Regulation, and Chemosensitization of Non-Hodgkin's Lymphoma B Cells by Rituximab
Cancer Res., October 1, 2004; 64(19): 7117 - 7126.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. Zhang and H. F. Lodish
Constitutive activation of the MEK/ERK pathway mediates all effects of oncogenic H-ras expression in primary erythroid progenitors
Blood, September 15, 2004; 104(6): 1679 - 1687.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
H. W. Cheung, M.-t. Ling, S. W. Tsao, Y.C. Wong, and X. Wang
Id-1-induced Raf/MEK pathway activation is essential for its protective role against taxol-induced apoptosis in nasopharyngeal carcinoma cells
Carcinogenesis, June 1, 2004; 25(6): 881 - 887.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
X. Ling, R. J. Bernacki, M. G. Brattain, and F. Li
Induction of Survivin Expression by Taxol (Paclitaxel) Is an Early Event, Which Is Independent of Taxol-mediated G2/M Arrest
J. Biol. Chem., April 9, 2004; 279(15): 15196 - 15203.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. P. MacKeigan, C. M. Clements, J. D. Lich, R. M. Pope, Y. Hod, and J. P-Y. Ting
Proteomic Profiling Drug-Induced Apoptosis in Non-Small Cell Lung Carcinoma: Identification of RS/DJ-1 and RhoGDI{alpha}
Cancer Res., October 15, 2003; 63(20): 6928 - 6934.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Litz, P. Carlson, G. S. Warshamana-Greene, S. Grant, and G. W. Krystal
Flavopiridol Potently Induces Small Cell Lung Cancer Apoptosis during S Phase in a Manner That Involves Early Mitochondrial Dysfunction
Clin. Cancer Res., October 1, 2003; 9(12): 4586 - 4594.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
W. Jia, C. Yu, M. Rahmani, G. Krystal, E. A. Sausville, P. Dent, and S. Grant
Synergistic antileukemic interactions between 17-AAG and UCN-01 involve interruption of RAF/MEK- and AKT-related pathways
Blood, September 1, 2003; 102(5): 1824 - 1832.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. J. Taxman, J. P. MacKeigan, C. Clements, D. T. Bergstralh, and J. P-Y. Ting
Transcriptional Profiling of Targets for Combination Therapy of Lung Carcinoma with Paclitaxel and Mitogen-activated Protein/Extracellular Signal-regulated Kinase Kinase Inhibitor
Cancer Res., August 15, 2003; 63(16): 5095 - 5104.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
L. C. Platanias
Map kinase signaling pathways and hematologic malignancies
Blood, June 15, 2003; 101(12): 4667 - 4679.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
K. Shimada, M. Nakamura, E. Ishida, M. Kishi, and N. Konishi
Roles of p38- and c-jun NH2-terminal kinase-mediated pathways in 2-methoxyestradiol-induced p53 induction and apoptosis
Carcinogenesis, June 1, 2003; 24(6): 1067 - 1075.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. Yu, M. Rahmani, J. Almenara, M. Subler, G. Krystal, D. Conrad, L. Varticovski, P. Dent, and S. Grant
Histone Deacetylase Inhibitors Promote STI571-mediated Apoptosis in STI571-sensitive and -resistant Bcr/Abl+ Human Myeloid Leukemia Cells
Cancer Res., May 1, 2003; 63(9): 2118 - 2126.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. Yu, M. Rahmani, Y. Dai, D. Conrad, G. Krystal, P. Dent, and S. Grant
The Lethal Effects of Pharmacological Cyclin-dependent Kinase Inhibitors in Human Leukemia Cells Proceed through a Phosphatidylinositol 3-Kinase/Akt-dependent Process
Cancer Res., April 15, 2003; 63(8): 1822 - 1833.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. Yu, G. Krystal, P. Dent, and S. Grant
Flavopiridol Potentiates STI571-induced Mitochondrial Damage and Apoptosis in BCR-ABL-positive Human Leukemia Cells
Clin. Cancer Res., September 1, 2002; 8(9): 2976 - 2984.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. P. MacKeigan, D. J. Taxman, D. Hunter, H. S. Earp III, L. M. Graves, and J. P-Y. Ting
Inactivation of the Antiapoptotic Phosphatidylinositol 3-Kinase-Akt Pathway by the Combined Treatment of Taxol and Mitogen-activated Protein Kinase Kinase Inhibition
Clin. Cancer Res., July 1, 2002; 8(7): 2091 - 2099.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
S. A. Holstein and R. J. Hohl
Synergistic Interaction of Lovastatin and Paclitaxel in Human Cancer Cells
Mol. Cancer Ther., December 1, 2001; 1(2): 141 - 149.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2001 by the American Society for Pharmacology and Experimental Therapeutics